Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K4 | O95819 | 4/20 | 0.58 |
| ▸ | HRH4 | Q9H3N8 | 14/20 | 0.47 |
| ▸ | DPP4 | P27487 | 1/20 | 0.42 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30834067 | 1.00 | MAP4K4 (0.58) | MAP4K4HRH4DPP4LRRK2HRH3 | |
| SCHEMBL27201273 | 0.88 | HRH4 (0.60) | MAP4K4HRH4HRH3 | |
| SCHEMBL27201358 | 0.88 | HRH4 (0.60) | MAP4K4HRH4HRH3 | |
| SCHEMBL30885260 | 0.88 | MAP4K4 (0.56) | MAP4K4HRH4DPP4HRH3 | |
| SCHEMBL30885319 | 0.88 | HRH4 (0.60) | MAP4K4HRH4HRH3 | |
| SCHEMBL30834211 | 0.88 | HRH4 (0.60) | MAP4K4HRH4HRH3 | |
| SCHEMBL27201310 | 0.88 | MAP4K4 (0.56) | MAP4K4HRH4DPP4HRH3 | |
| SCHEMBL27201419 | 0.85 | HRH4 (0.55) | MAP4K4HRH4DPP4LRRK2HRH3 | |
| SCHEMBL30885272 | 0.85 | HRH4 (0.55) | MAP4K4HRH4DPP4LRRK2HRH3 | |
| SCHEMBL30885255 | 0.79 | MAP4K4 (0.53) | MAP4K4HRH4DPP4LRRK2HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240132464-A1 | HETEROCYCLIC COMPOUNDS AS E3 LIGASE INHIBITORS | ACCUTAR BIOTECHNOLOGY INC. (US) | 2024-04-25 | — | — | US | claimed |
| US-20240132464-A1 | HETEROCYCLIC COMPOUNDS AS E3 LIGASE INHIBITORS | ACCUTAR BIOTECHNOLOGY INC. (US) | 2024-04-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240132464-A1 | HETEROCYCLIC COMPOUNDS AS E3 LIGASE INHIBITORS | GID4, MDM2, XIAP | MAP4K4 1878/4885HRH4 4074/4885DPP4 509/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.